Drugs / haNK for Infusion
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03387085 Background | Mar 2018 → Sep 2020 | triple-negative breast carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | haNK for Infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03387085 ↗ |
| Modality | Cell therapy | “NK-92 \[CD16.158V, ER IL-2\]” NCT03387085 ↗ |